Skip to content
Sample Page
Author:
Biolojic Design
Posted Date:
April 17, 2026
Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting
Biolojic Design
April 17, 2026
Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)
Biolojic Design
March 25, 2026
